To date, a limited number of studies have been published in Sudan concerning inter-individual and inter-ethnic differences in NAT2 allele frequencies, (Ali et al., 2019; Al-Yahyaee et al., 2007) but this is the first investigation into its genetic variations (481 C→T, 590 G→A, 803 A→G and 857G→A) and their association with CML susceptibility and progression (Kotila et al., 2019). This evidence concerns the gene NAT2 and chronic myelogenous leukemia, BCR-ABL1 positive.